Pathobiological Implications of MUC16 Expression in Pancreatic Cancer (original) (raw)
Figure 1
The expression of MUC16 in normal (N) and pancreatic cancer (PC) tissues by immunohistochemistry.
The tissue sections were obtained from ACCUMAX in the form of an array and were stained with anti-MUC16 monoclonal antibody. The stained sections were observed under the microscope and the immunoreactivity was judged by the intensity and spread of the dark stain. Anti-MUC16 antibody showed no staining in the normal pancreas tissue (both ducts and acini) while a strong staining was observed in the cancerous tissues. (A) Box plot representing the score of MUC16 across the various grades of PC. From the box plot we observed the immunoreactivity to be higher in the poorly (D) and moderately differentiated (C) tissues in comparison to well differentiated (B) tissues. The normal pancreas (A) tissue is also negative. Representative sections demonstrating MUC16 expression in normal pancreatic ducts and various grades of invasive adenocarcinoma are shown. Note the predominant membrane staining of MUC16 in PC. (B) Expression studies of MUC16 in normal, pancreatitis and pancreatic cancer tissues by RT-PCR. RT-PCR was performed on mRNA isolated from normal human pancreatic tissue (N1, N2), human pancreatitis tissue (Pt1–Pt6) and human pancreatic cancer tissue (PC1–PC17). No amplification was observed in the normal tissues but amplification was observed in the pancreatic cancer and pancreatitis tissues. Actin was used as an internal control.